ClinicalTrials.gg
CompletedNCT01429818Updated Sep 7, 2011

Endothelial Disfunction Treatment With Glimepiride/Metformin Combination (Glimetal) in Type 2 Diabetes Patients

A Phase 4 interventional study of Glimepiride/metformin and Metformin in Endothelial Dysfunction and Diabetes Mellitus, sponsored by Laboratorios Silanes S.A. de C.V.. Completed at 1 site in Mexico. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2011-09-07.

Sponsored by Laboratorios Silanes S.A. de C.V. · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
16
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 14 studies testing glimepiride in Diabetes Mellitus — 1 open to participants now, 1 under way, none of them phase 3. glimepiride · Diabetes Mellitus.

Enrollment
14th of 14
16 · median 286
Started
2007
the only one that year
Phase 4
5 of 14
none open now
Registered
10th of 14
by date
Lead sponsor
1 of 14
Laboratorios Silanes S.A. de C.V.

Among the 14 studies testing glimepiride in Diabetes Mellitus, this one is the 14th largest by enrollment, is the only one that started in 2007, is one of 5 in phase 4, and was the 10th registered.

Diabetes Mellitus

8,294 studies on the registry are indexed under Diabetes Mellitus; 1,072 are open to participants now.

Browse Diabetes Mellitus studies →

Open to participants now

1 of the 14 studies testing glimepiride in Diabetes Mellitus is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About glimepiride

glimepiride: first FDA approval 1995 (AMARYL), first EMA approval 2006. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 649 Diabetes Mellitus studies recruiting now, 359 (55%) set no upper age limit and 194 (30%) stop at 75 or younger; 89 take children under 18; 181 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies testing glimepiride in Diabetes Mellitus, or all of them as a file.
02

Study summary

The Purpose of this study was to evaluate the effect of the combination glimepiride/metformin over endothelial dysfunction (ED) in asymptomatic patients with type 2 diabetes mellitus (DM) using 13N-ammonia-positron emission tomography (PET).

03

Conditions studied

  • Endothelial Dysfunction
  • Diabetes Mellitus

Browse trials for

Keywords

  • Endothelial dysfunction
  • Diabetes mellitus
  • glimepiride
  • metformin
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Both genders
  • At least 18 years old
  • Type 2 diabetes mellitus diagnosis
  • Signed

Exclusion criteria

Exclusion Criteria:

  • History of smoking, hypertension, dyslipidemia, ischemic heart disease or rheumatic diseases
  • Pregnancy or lactation
  • History of abuse and/or substance dependence within 6 months preceding the survey.
  • History of glimepiride or metformin allergy
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
16 participants (actual)

Study arms

  • Experimental
    Glimepiride/metformin

    Drug: Glimepiride/metformin

  • Active comparator
    Metformin

    Drug: Metformin

Interventions

  • DrugGlimepiride/metformin

    Drug pages: Glimepiride · Metformin

    4/1000 mg tablets once a day foe eight weeks

    Also known as: GLIMETAL

  • 1000 mg tablets once daily for eight weeks

    Also known as: PREDIAL

06

What researchers measure

Primary outcomes

  1. EDVI

    endothelial-dependent vasodilation index

    Time frame: 8 weeks

  2. MFR

    myocardial flow reserve

    Time frame: 8 weeks

  3. %ΔMBF

    percentage of the change between rest and CPT

    Time frame: 8 weeks

Secondary outcomes

  1. Fasting glucose

    Time frame: 8 weeks

  2. Glycated hemoglobin

    Time frame: 8 weeks

  3. Adverse effects

    Time frame: 8 weeks

07

Study locations

1 site
  • Unidad PET Ciclotrón. Facultad de Medicina. Universidad Nacional Autónoma de México
    Mexico city, Distrito Federal 04510, Mexico
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2007, a primary completion of Jan 2008 and a completion of Jan 2008. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 5, 2011
First posted
Sep 7, 2011
Start
Jul 2007
Primary completionActual
Jan 2008
CompletionActual
Jan 2008
Last update
Sep 7, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 7, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01429818
Responsible party
Sponsor
First posted
Sep 7, 2011
Start date
Jul 2007
Primary completion
Jan 2008
Completion
Jan 2008
Last update
Sep 7, 2011

Study contacts

Jorge González, MD
study director · Laboratorios Silanes S.A. de C.V.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Glimepiride · Metformin

Start the discussion